Pharmacquired: Splashy deals belie a shallow pool of heart drugs left to acquire

Two big deals for heart drugs in less than a year might give the impression that more could soon follow.

But what Bristol Myers Squibb did this Monday with its $13 billion bid for MyoKardia, and what Novartis did last November with its $10 billion buy of The Medicines Co., was thin an already shallow pool of biotechs that work on cardiovascular drugs. With relatively few left to pick from, industry followers expect some time to pass before they see a steady stream of M&A.